189 related articles for article (PubMed ID: 28599191)
1. Targeting autophagy in multiple myeloma.
Yun Z; Zhichao J; Hao Y; Ou J; Ran Y; Wen D; Qun S
Leuk Res; 2017 Aug; 59():97-104. PubMed ID: 28599191
[TBL] [Abstract][Full Text] [Related]
2. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
3. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
[TBL] [Abstract][Full Text] [Related]
4. MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.
Zhang L; Rastgoo N; Wu J; Zhang M; Pourabdollah M; Zacksenhaus E; Chen Y; Chang H
Cancer Lett; 2020 Jun; 480():29-38. PubMed ID: 32220540
[TBL] [Abstract][Full Text] [Related]
5. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.
Riz I; Hawley TS; Hawley RG
Oncotarget; 2015 Jun; 6(17):14814-31. PubMed ID: 26109433
[TBL] [Abstract][Full Text] [Related]
6. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
[TBL] [Abstract][Full Text] [Related]
7. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
8. Control of autophagic cell death by caspase-10 in multiple myeloma.
Lamy L; Ngo VN; Emre NC; Shaffer AL; Yang Y; Tian E; Nair V; Kruhlak MJ; Zingone A; Landgren O; Staudt LM
Cancer Cell; 2013 Apr; 23(4):435-49. PubMed ID: 23541952
[TBL] [Abstract][Full Text] [Related]
9. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
de Oliveira MB; Sanson LFG; Eugenio AIP; Barbosa-Dantas RSS; Colleoni GWB
Curr Mol Med; 2019; 19(2):112-119. PubMed ID: 30834832
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition in multiple myeloma: lessons for other cancers.
Saavedra-García P; Martini F; Auner HW
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C451-C462. PubMed ID: 31875696
[TBL] [Abstract][Full Text] [Related]
11. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
12. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
13. Autophagy and Myeloma.
Zheng Z; Wang L; Cheng S; Wang Y; Zhao W
Adv Exp Med Biol; 2020; 1207():625-631. PubMed ID: 32671780
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
15. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Moriya S; Komatsu S; Yamasaki K; Kawai Y; Kokuba H; Hirota A; Che XF; Inazu M; Gotoh A; Hiramoto M; Miyazawa K
Int J Oncol; 2015 Feb; 46(2):474-86. PubMed ID: 25422130
[TBL] [Abstract][Full Text] [Related]
16. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
Archer CR; Koomoa DL; Mitsunaga EM; Clerc J; Shimizu M; Kaiser M; Schellenberg B; Dudler R; Bachmann AS
Biochem Pharmacol; 2010 Jul; 80(2):170-8. PubMed ID: 20362557
[TBL] [Abstract][Full Text] [Related]
17. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
18. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
19. Essential amino acid mixtures drive cancer cells to apoptosis through proteasome inhibition and autophagy activation.
Bonfili L; Cecarini V; Cuccioloni M; Angeletti M; Flati V; Corsetti G; Pasini E; Dioguardi FS; Eleuteri AM
FEBS J; 2017 Jun; 284(11):1726-1737. PubMed ID: 28391610
[TBL] [Abstract][Full Text] [Related]
20. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]